{"disease":{"id":"bone-metastases-from-solid-tumors","name":"bone metastases from solid tumors"},"drugs":{"marketed":[{"drug_id":"zoledronic-acid","indication_name":"Bone Metastases from Solid Tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zometa","generic_name":"ZOLEDRONIC ACID","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Farnesyl pyrophosphate synthase","drug_class":"zoledronic acid","quality_score":80,"revenue":null,"mechanism":"Zometa works by inhibiting the enzyme farnesyl pyrophosphate synthase, which is involved in the mevalonate pathway and ultimately leads to the inhibition of osteoclast activity."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04859569","title":"Efficacy and Safety of LY01011 and Xgeva® in Patients With Bone Metastases From Solid Tumors","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":850,"lead_sponsor_name":"Luye Pharma Group Ltd.","has_results":false},{"nct_id":"NCT04630522","title":"Efficacy and Safety of JMT103 in Patients With Bone Metastases From Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":295,"lead_sponsor_name":"Shanghai JMT-Bio Inc.","has_results":false},{"nct_id":"NCT07112989","title":"Development of Innovative Preclinical Ex Vivo Models for the Study of Sarcomas and Metastases From Solid Tumors","phase":"","overall_status":"RECRUITING","enrollment_count":125,"lead_sponsor_name":"Istituto Ortopedico Rizzoli","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}